Siemens Unveils MR Oncology Applications and Dedicated Breast ... International Business Times, NY - Nov 30, 2008 ... detectionof prostate cancer(*). syngo Tissue 4D offers dynamic evaluation with quantification of tumortissues in organs, such as the prostate and liver. ...
Akron girl is graceful with gifts Akron Beacon Journal, OH - Bob, who has end-stage cirrhosis as a result of hepatitis C, desperately needs a liver transplant. Alexis, who suffers from myelodysplastic syndrome, ...
Liver disease tackled with dedicated ?1m unit Imperial College London, UK - Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology ...
Doctor waits for court dates Scranton Times-Tribune, USA - Ms. Rogers was admitted to Marian Community Hospital in August 2006, where staffers discovered she had breast cancer that had spread to her lungs, liver and ...
Cancer sufferer praises hospice for special care Grimsby Telegraph, UK - She added: ?Now I have cancer in my liver, lung, bones and head. ?I had chemotherapy for 13 months but it made me really ill. ?The toxins had built up in my ...
Recent News and Articles on the Keywords: liver + cancer + against Related to the article below (Last Update: 8/7/2008)
Cancer Patient Says Insurance Won't Pay Up KMBC.com, MO - A Northland woman was diagnosed with a rare liver cancer, and she said her insurance company won't cover her treatments. Russ Howard has been with his wife, ...
Doctor explains new treatment for liver cancer Inquirer.net, Philippines - Now that we've launched our INQUIRER.net VDO service, we'd like to get your feedback so that we could further improve it. How would you rate the loading ...
Onyx sees first back-to-back profit Inside Bay Area, CA - Liver cancer kills more than 660000 people a year worldwide, making it the third most deadly tumor, according to the World Health Organization. ...ONXX - OTC:BAYRY
Is Coffee the Elixir of Life? Miller-McCune.com, CA - Aug 5, 2008 Is the grim specter of liver cancer keeping you up at night? That morning cup of joe (or five or six) just might be what the doctor ordered. ...
Pasig hospital offers fresh hope to liver cancer patients Inquirer.net, Philippines - Aug 1, 2008 By Beverly T. Natividad MANILA, Philippines ? A new technology introduced recently in the Philippines offers new hope to Filipinos with liver cancer, ...
Onyx Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Aug 5, 2008 The first stage of our launch in liver cancer has been very successful as we are rapidly penetrating the traditional oncology segment of this indication in ...ONXX
Diabetes mellitus and the risk of primary liver cancer - C La Vecchia, E Negri, A Decarli, S Franceschi - International Journal of Cancer, 1997 - doi.wiley.com ... The observation that the risk of livercancer was elevated several years after
diagnosis of diabetes, in any case, weighs against the hypothesis that earlier ...
Risk Factors for the Rising Rates of Primary Liver Cancer in the United States - HB El-Serag, AC Mason - Archives of Internal Medicine, 2000 - Am Med Assoc ... types of primary livercancer. However, the use of this code in the VA PTF to study
cases of hepatocellular carcinoma has been validated against the National ...
Chemoprotection against cancer by Phase 2 enzyme induction - P Talalay, JW Fahey, WD Holtzclaw, T Prestera, Y … - Toxicology Letters, 1995 - Elsevier ... and bifunctional anticar- cinogenic enzyme inducers in murine liver. Cancer Res. ...
S-transferase activities and protection against mutagenic metabolites of benzo ...
Rapid detection of inducers of enzymes that protect against carcinogens - HJ Prochaska, AB Santamaria, P Talalay - Proc Natl Acad Sci US A, 1992 - pubmedcentral.nih.gov ... regulating the induction of enzymes that protect against chemical carcinogenesis. ...
and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res ...
Researchers have identified a new compound called CDDO-Im that protects against the development of liver cancer in laboratory animals.
Experiments, led by researchers at the Johns Hopkins Bloomberg School of Public Health, showed CDDO-Im to be effective at doses 100 times lower than other compounds known to prevent cancer in people.
Because of its makeup, the researchers believe CDDO-Im could be particularly effective in preventing cancers with a strong link to inflammation, such as liver, colon, prostate and gastric cancers. It could also play a role in preventing diseases such as neurodegeneration, asthma and emphysema.
The findings are featured in the journal Cancer Research.
CDDO-Im is a synthetic compound that belongs to a class of cancer-fighting compounds called triterpenoids under development by Michael Sporn and other study co-authors at Dartmouth Medical School.
It is derived from oleanolic acid, a naturally occurring substance found in many plants. Other oleanolic derivatives are known to reduce tumor growth in animals and humans.
Researchers believe CDDO-Im works by activating Nrf2, a master switch known to direct certain enzymes to stimulate the cell's defense mechanisms and remove harmful chemicals from cells. "Activation of the Nrf2 pathway with CDDO-Im could provide protection against a number of diseases triggered by environmental agents," said Thomas Kensler, at the Bloomberg School's Department of Environmental Health Sciences and lead author of the study.
In their research, Kensler and his colleagues treated laboratory rats with varying doses of CDDO-Im.
Two days after treatment with CDDO-Im, the rats were given aflatoxin, a naturally occurring cancer-causing toxin. CDDO-Im treatment led to an 85 percent reduction in pre-cancerous lesions at the lowest dose of 50 micrograms per rat and a 99 percent reduction at the highest dose of 5 milligrams.
Like other compounds derived from oleanolic acid, CDDO-Im also has strong anti-inflammatory properties, which the researchers say makes it ideally suited to the prevention of certain cancers.
" When cells become inflamed, they can produce reactive molecules, called free radicals, that can damage DNA and promote cancer development," explained Kensler. " CDDO-Im can also inhibit cancer formation by interfering with this inflammatory process."
Because it can stimulate the body's defense mechanisms at such low doses, Kensler believes that CDDO-Im is an excellent candidate for cancer prevention in humans.
" If this compound can produce such a potent and dramatic reduction in the number of pre-cancerous growths, it should have an equally dramatic impact on the development of actual cancers. This study suggests that we may be on the right track in terms of chemoprevention. It may open the door for a new class of compounds that could prevent a number of diseases," said Kensler.
Source: Johns Hopkins University Bloomberg School of Public Health, 2006
